Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Diamyd(R) Phase III Study Approved For Younger Patients In The US
Diamyd Medical reported that the company has received approval from the US Food and Drug Administration (FDA) to include children with type 1 diabetes from 10 years of age in the company"s Phase III study with the diabetes vaccine Diamyd(R).
generic viagra online
How Much Health Care For $1 Trillion?
USA Today asks what the additional $1 trillion cost of a health care overhaul (over 10 years) will actually buy. "Although the eye-popping price tag would help boost insurance coverage to 95% or more of the public, it"s not enough to do everything advocates initially want. The proposals being shaped in Congress - including the $1.042 trillion bill unveiled by House Democratic leaders Tuesday - offer subsidies to fewer moderate-income families than originally intended, bar most workers from choosing to leave their employer-provided plans and likely drive up Medicaid costs for states." The Congressional Budget Office estimates that "at the end of a decade, 15 million to 20 million would remain uninsured."
News of the day
New Internet Survey Reveals That Almost 8 Out Of 10 UK Doctors Feel Alzheimer's Disease Is Undertreated
The IMPACT (Important Perspectives on Alzheimer"s Care & Treatment) study explored the views of 1800 people - physicians (GPs and specialists),1 Alzheimer"s carers,1 payors1 and the general public1 in France, Germany, Italy, Spain and the UK
Nutrition

Baxter Advances To Full-Scale Production Of A/H1N1 Vaccine

Baxter International Inc. (NYSE: BAX) announced that it has completed testing and evaluation of the A/H1N1 influenza virus and is now in full-scale production of a commercial A/H1N1 vaccine using its Vero cell culture technology. Baxter received an A/H1N1 strain from the U.S. Centers for Disease Control and Prevention [a World Health Organization (WHO) Collaborating Center] in early May and is diligently working to deliver a pandemic vaccine for use as early as July. WHO raised the pandemic alert level to phase 6, indicating a global influenza pandemic involving the 2009 A/H1N1 strain. Baxter is in contact with WHO and other global public health authorities regarding the pandemic. A number of national public health authorities have existing pandemic agreements with Baxter that allow them to place orders for a vaccine now that a pandemic has been declared by WHO. These public health authorities will be evaluating their needs to determine their orders for vaccine supply. Despite the company"s existing obligations to supply vaccine under a pandemic phase 6 alert, Baxter is also committed to working with WHO to allocate a portion of the company"s commercial production to address global public health issues deemed most urgent. Using its Vero cell technology, Baxter has received European Medicines Agency (EMEA) approval for a mock-up pandemic vaccine called CELVAPAN, the brand name for the company"s pandemic vaccine. The qualification, development and manufacturing processes used in gaining mock-up licensure for CELVAPAN apply as the company uses this new influenza A/H1N1 virus strain to produce a pandemic vaccine. The CELVAPAN EMEA licensure supports fast track approval of a pandemic vaccine containing the A/H1N1 virus strain. Baxter will submit the A/H1N1 vaccine for approval upon completion of initial manufacturing runs. Baxter"s research and development, manufacturing capabilities and pandemic planning expertise allow the company to efficiently develop candidate vaccines against potentially emerging influenza viruses. Baxter believes that its Vero cell technology can be used to safely and reliably produce a vaccine in response to this global public health issue. It is possible that Baxter"s Vero cell technology may offer advantages, in that it may allow more rapid production and delivery of pandemic vaccines. Baxter International Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009